GlassScriptPhysician profile
Jo-Ann M Moore
NPI 1104134113
$2,586.98
in general payments reported to CMS, 2019-2025
19 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.27 · 2022: $926 · 2023: $32.70 · 2024: $1,397 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874 · Travel and Lodging: $518 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.55 |
| Travel and Lodging | $518.33 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $768.33 | 2024 | |
| Astellas Pharma US INC | $396.52 | 2022-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $301.45 | 2023-2025 | Gemtesa |
| 180 Medical, INC. | $166.21 | 2022-2024 | |
| Abbvie INC. | $129.38 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.15 | 2024 | |
| Endo USA, INC. | $111.65 | 2024-2025 | Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $111.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $103.96 | 2022 | |
| Tolmar, INC. | $61.09 | 2024-2025 | Eligard, Jatenzo |
| Olympus America INC. | $58.05 | 2022 | |
| Endo Pharmaceuticals INC. | $44.80 | 2022-2024 | Aveed, Xiaflex |
| Urovant Sciences INC | $43.19 | 2022 | |
| Antares Pharma, INC. | $43.11 | 2022 | |
| Myovant Sciences INC. | $35.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $34.94 | 2022 | |
| United Therapeutics Corporation | $19.27 | 2021 | |
| Pfizer INC. | $16.94 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.78 | 2025 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo-Ann Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.